Literature DB >> 28490586

Deletion of the K1L Gene Results in a Vaccinia Virus That Is Less Pathogenic Due to Muted Innate Immune Responses, yet Still Elicits Protective Immunity.

Ariana G Bravo Cruz1, Aiguo Han2, Edward J Roy3, Arielle B Guzmán1, Rita J Miller2, Elizabeth A Driskell4, William D O'Brien2, Joanna L Shisler5.   

Abstract

All viruses strategically alter the antiviral immune response to their benefit. The vaccinia virus (VACV) K1 protein has multiple immunomodulatory effects in tissue culture models of infection, including NF-κB antagonism. However, the effect of K1 during animal infection is poorly understood. We determined that a K1L-less vaccinia virus (vΔK1L) was less pathogenic than wild-type VACV in intranasal and intradermal models of infection. Decreased pathogenicity was correlated with diminished virus replication in intranasally infected mice. However, in intradermally inoculated ears, vΔK1L replicated to levels nearly identical to those of VACV, implying that the decreased immune response to vΔK1L infection, not virus replication, dictated lesion size. Several lines of evidence support this theory. First, vΔK1L induced slightly less edema than vK1L, as revealed by histopathology and noninvasive quantitative ultrasound technology (QUS). Second, infiltrating immune cell populations were decreased in vΔK1L-infected ears. Third, cytokine and chemokine gene expression was decreased in vΔK1L-infected ears. While these results identified the biological basis for smaller lesions, they remained puzzling; because K1 antagonizes NF-κB in vitro, antiviral gene expression was expected to be higher during vΔK1L infection. Despite these diminished innate immune responses, vΔK1L vaccination induced a protective VACV-specific CD8+ T cell response and protected against a lethal VACV challenge. Thus, vΔK1L is the first vaccinia virus construct reported that caused a muted innate immune gene expression profile and decreased immune cell infiltration in an intradermal model of infection yet still elicited protective immunity.IMPORTANCE The vaccinia virus (VACV) K1 protein inhibits NF-κB activation among its other antagonistic functions. A virus lacking K1 (vΔK1L) was predicted to be less pathogenic because it would trigger a more robust antiviral immune response than VACV. Indeed, vΔK1L was less pathogenic in intradermally infected mouse ear pinnae. However, vΔK1L infection unexpectedly elicited dramatically reduced infiltration of innate immune cells into ears. This was likely due to decreased expression of cytokine and chemokine genes in vΔK1L-infected ears. As such, our finding contradicted observations from cell culture systems. Interestingly, vΔK1L conferred protective immunity against lethal VACV challenge. This suggests that the muted immune response triggered during vΔK1L infection remained sufficient to mount an effective protective response. Our results highlight the complexity and unpredictable nature of virus-host interactions, a relationship that must be understood to better comprehend virus pathogenesis or to manipulate viruses for use as vaccines.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  K1L; poxvirus; vaccines; vaccinia virus; viral pathogenesis; virus-host interactions

Mesh:

Substances:

Year:  2017        PMID: 28490586      PMCID: PMC5512244          DOI: 10.1128/JVI.00542-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  75 in total

1.  MyD88-dependent immunity to a natural model of vaccinia virus infection does not involve Toll-like receptor 2.

Authors:  Michael L Davies; Janet J Sei; Nicholas A Siciliano; Ren-Huan Xu; Felicia Roscoe; Luis J Sigal; Laurence C Eisenlohr; Christopher C Norbury
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

2.  Vaccinia virus gene B7R encodes an 18-kDa protein that is resident in the endoplasmic reticulum and affects virus virulence.

Authors:  N Price; D C Tscharke; M Hollinshead; G L Smith
Journal:  Virology       Date:  2000-02-01       Impact factor: 3.616

3.  A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae.

Authors:  David C Tscharke; Geoffrey L Smith
Journal:  J Gen Virol       Date:  1999-10       Impact factor: 3.891

4.  Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model.

Authors:  T A Brandt; B L Jacobs
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

5.  The vaccinia virus A4OR gene product is a nonstructural, type II membrane glycoprotein that is expressed at the cell surface.

Authors:  Diane Wilcock; Stephen A Duncan; Paula Traktman; Wei-Hong Zhang; Geoffrey L Smith
Journal:  J Gen Virol       Date:  1999-08       Impact factor: 3.891

6.  The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence.

Authors:  Nathan Bartlett; Julian A Symons; David C Tscharke; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2002-08       Impact factor: 3.891

7.  CXCR3 chemokine receptor enables local CD8(+) T cell migration for the destruction of virus-infected cells.

Authors:  Heather D Hickman; Glennys V Reynoso; Barbara F Ngudiankama; Stephanie S Cush; James Gibbs; Jack R Bennink; Jonathan W Yewdell
Journal:  Immunity       Date:  2015-03-10       Impact factor: 31.745

Review 8.  Reflections on the early development of poxvirus vectors.

Authors:  Bernard Moss
Journal:  Vaccine       Date:  2013-04-10       Impact factor: 3.641

9.  EVM005: an ectromelia-encoded protein with dual roles in NF-κB inhibition and virulence.

Authors:  Nicholas van Buuren; Kristin Burles; Jill Schriewer; Ninad Mehta; Scott Parker; R Mark Buller; Michele Barry
Journal:  PLoS Pathog       Date:  2014-08-14       Impact factor: 6.823

10.  Inhibition of Translation Initiation by Protein 169: A Vaccinia Virus Strategy to Suppress Innate and Adaptive Immunity and Alter Virus Virulence.

Authors:  Pavla Strnadova; Hongwei Ren; Robert Valentine; Michela Mazzon; Trevor R Sweeney; Ian Brierley; Geoffrey L Smith
Journal:  PLoS Pathog       Date:  2015-09-03       Impact factor: 6.823

View more
  6 in total

1.  Low fat but not soy protein isolate was an effective intervention to reduce nonalcoholic fatty liver disease progression in C57BL/6J mice: monitored by a novel quantitative ultrasound (QUS) method.

Authors:  Joe L Rowles; Aiguo Han; Rita J Miller; Jamie R Kelly; Catherine C Applegate; Matthew A Wallig; William D O'Brien; John W Erdman
Journal:  Nutr Res       Date:  2018-12-14       Impact factor: 3.315

2.  A comparison of the effect of molluscum contagiosum virus MC159 and MC160 proteins on vaccinia virus virulence in intranasal and intradermal infection routes.

Authors:  Sunetra Biswas; Geoffrey L Smith; Edward J Roy; Brian Ward; Joanna L Shisler
Journal:  J Gen Virol       Date:  2018-02       Impact factor: 3.891

3.  Vaccinia Virus Encodes a Novel Inhibitor of Apoptosis That Associates with the Apoptosome.

Authors:  Melissa R Ryerson; Monique M Richards; Marc Kvansakul; Christine J Hawkins; Joanna L Shisler
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

4.  Ectromelia virus lacking the E3L ortholog is replication-defective and nonpathogenic but does induce protective immunity in a mouse strain susceptible to lethal mousepox.

Authors:  Tiffany R Frey; Katherine S Forsyth; Maura M Sheehan; Brian C De Haven; Julia G Pevarnik; Erin S Hand; Marie C Pizzorno; Laurence C Eisenlohr; Adam R Hersperger
Journal:  Virology       Date:  2018-03-27       Impact factor: 3.616

Review 5.  Modulating Vaccinia Virus Immunomodulators to Improve Immunological Memory.

Authors:  Jonas D Albarnaz; Alice A Torres; Geoffrey L Smith
Journal:  Viruses       Date:  2018-02-28       Impact factor: 5.048

Review 6.  Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.

Authors:  Zong Sheng Guo; Binfeng Lu; Zongbi Guo; Esther Giehl; Mathilde Feist; Enyong Dai; Weilin Liu; Walter J Storkus; Yukai He; Zuqiang Liu; David L Bartlett
Journal:  J Immunother Cancer       Date:  2019-01-09       Impact factor: 13.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.